T-Cell PET Imaging With [18F]F-AraG in Lung Cancer

Summary

This is a single-center cross-sectional imaging study in patients with localized lung cancer undergoing immunotherapy with or without stereotactic radiation therapy as part of the companion clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer). Each patient will undergo a single \[18F\]F-AraG PET exam as part of this study. \[18F\]F-AraG will be administered at a single time point intravenously prior to PET imaging. Whole-body PET will be acquired along with a whole body low dose CT (PET/CT) used for attenuation correction and anatomic localization of \[18F\]F-AraG uptake, SUV calculation, and volumetric selection for radiomic analyses.

Timeline

Start

2017-11-26

Primary completion

2019-10-15

Completion

2019-10-15

Outcome

Outcome not reported

Stopped (Enrollment): “Low Accrual”

Drugs

Indications